Hims & Hers Health (NYSE:HIMS) Faces Class Action After Partnership Termination With Novo Nordisk

Hims & Hers Health (NYSE:HIMS) has experienced a tumultuous quarter, marked by Novo Nordisk's termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company's share price. This partnership termination, alongside a class action lawsuit alleging misleading statements about safety and operational risks, contributed to heightened market volatility. Despite a remarkable quarterly earnings report with substantial sales and net income growth, these positive results were not enough to counter the adverse effects of legal and partnership challenges, as evidenced by the overall 30% price move compared to a 2% market rise.

You should learn about the 1 warning sign we've spotted with Hims & Hers Health.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource.

The recent developments involving Hims & Hers Health, particularly the partnership termination with Novo Nordisk and the class action lawsuit, could substantially alter the company's projected growth trajectory. These events may influence the narrative of future revenue and earnings, as they introduce uncertainties around safety and operations. The fallout from these challenges might stymie anticipated gains from the company's AI and personalized treatment initiatives, and could potentially disrupt the planned expansion into chronic condition markets.

Hims & Hers shares have demonstrated substantial resilience over a longer-term horizon, with a very large total shareholder return of 792.46% over three years. This indicates strong historical performance amidst present volatility, setting it apart in performance metrics compared to peers and markets. Although it surpassed the US healthcare industry, which saw a decline of 18.5% over the past year, it faces pressure to justify its future earnings potential amidst current challenges.

The latest news implicating safety and operational integrity could necessitate reevaluation of revenue and earnings forecasts. The analysts' future projections, which included expectations of significant revenue growth and margin improvements, might be impacted by these unfolding events, casting doubt on their sustainability. Furthermore, given the current share price movement and the disparities in analyst price targets, with a consensus of $48.53, the company's journey to align its market position with these targets seems increasingly complex. With the analysts projecting a 17.19% discount to the price target, market confidence in future growth must counteract the recent adverse headlines to achieve such valuations.

Understand Hims & Hers Health's track record by examining our performance history report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com